Cochrane · systematic review · CD008901
Recombinant growth hormone therapy for cystic fibrosis in children and young adults
Thaker, V, Carter, B, Putman, M · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
27
No studies
1
Included studies
NR
No studies 1 · 3.6%Ungraded 0 · 0%Very low 9 · 32.1%Low 18 · 64.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsStandard rhGH compared to placebo for cystic fibrosis in children and young adults
Population: children and young adults with CF
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1 (% predicted) change since baseline Standard rhGH vs placebo | no estimate extracted | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
FVC (% predicted) change since baseline Standard rhGH vs placebo | no estimate extracted | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Height velocity (cm/year) Standard rhGH vs placebo | no estimate extracted | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Weight (kg) Change from baseline Standard rhGH vs placebo | no estimate extracted | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
QoL Standard rhGH vs placebo | no estimate extracted | NR | Very low Downgraded: risk of bias, imprecision |
Fasting blood glucose (mg/dL) Standard rhGH vs placebo | no estimate extracted | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Number of pulmonary exacerbations or hospitalisations Standard rhGH vs placebo | RR 1.5 [0.49, 4.59] | 1 study · 44 participants | Low Downgraded: risk of bias, imprecision |
Standard rhGH compared to no treatment for cystic fibrosis in children and young adults
Population: children and young adults with CF
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1(% predicted) Standard rhGH vs no treatment | no estimate extracted | 1 study · 19 participants | Very low Downgraded: risk of bias, imprecision |
FVC (% predicted) Standard rhGH vs no treatment | no estimate extracted | 1 study · 19 participants | Very low Downgraded: risk of bias, imprecision |
Height velocity (cm/year) Standard rhGH vs no treatment | no estimate extracted | 4 studies · 156 participants | Very low Downgraded: risk of bias, imprecision |
Weight (kg) Change from baseline Standard rhGH vs no treatment | no estimate extracted | 1 study · 62 participants | Very low Downgraded: risk of bias, imprecision |
QoL Change from baseline Standard rhGH vs no treatment | no estimate extracted | 1 study · 57 participants | Very low Downgraded: risk of bias, imprecision |
Fasting blood glucose (mg/dL) Standard rhGH vs no treatment | no estimate extracted | 3 studies · 92 participants | Very low Downgraded: risk of bias, imprecision |
Number of pulmonary exacerbations or hospitalisations Standard rhGH vs no treatment | no estimate extracted | 3 studies · 94 participants | Very low Downgraded: risk of bias, imprecision |
High‐dose rhGH compared to placebo for children and young adults with cystic fibrosis
Population: children and young adults with CF
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1 (% predicted) Change from baseline High‐dose rhGH vs placebo | no estimate extracted | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |
FVC (% predicted) Change from baseline High‐dose rhGH vs placebo | no estimate extracted | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |
Height velocity (cm/year) High‐dose rhGH vs placebo | no estimate extracted | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |
Weight (kg) Change from baseline High‐dose rhGH vs placebo | no estimate extracted | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |
QoL High‐dose rhGH vs placebo | no estimate extracted | 1 study · 41 participants | Very low Downgraded: risk of bias, imprecision |
Fasting blood glucose (mg/dL) High‐dose rhGH vs placebo | no estimate extracted | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |
Number of pulmonary exacerbations or hospitalisations High‐dose rhGH vs placebo | RR 1.92 [0.66, 5.61] | 1 study · 42 participants | Low Downgraded: risk of bias, imprecision |
High‐dose rhGH compared to standard‐dose rhGH for children and young adults with cystic fibrosis
Population: children and young adults with CF
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1 (% predicted) Change from baseline High‐dose rhGH vs standard‐dose rhGH | no estimate extracted | 1 study · 42 participants | Low Downgraded: risk of bias, imprecision |
FVC (% predicted) Change from baseline High‐dose rhGH vs standard‐dose rhGH | no estimate extracted | 1 study · 42 participants | Low Downgraded: risk of bias, imprecision |
Height velocity (cm/year) High‐dose rhGH vs standard‐dose rhGH | no estimate extracted | 1 study · 42 participants | Low Downgraded: risk of bias, imprecision |
Weight (kg) Change from baseline High‐dose rhGH vs standard‐dose rhGH | no estimate extracted | 1 study · 42 participants | Low Downgraded: risk of bias, imprecision |
QoL High‐dose rhGH vs standard‐dose rhGH | no estimate extracted | NR | No studies |
Fasting blood glucose (mg/dL) High‐dose rhGH vs standard‐dose rhGH | no estimate extracted | 1 study · 42 participants | Low Downgraded: risk of bias, imprecision |
Number of pulmonary exacerbations or hospitalisations High‐dose rhGH vs standard‐dose rhGH | RR 1.28 [0.52, 3.18] | 1 study · 42 participants | Low Downgraded: risk of bias, imprecision |